文献速递新发突发、热带与寄生虫病

羟氯喹体外抗SARS-CoV-2活性及优化给药方案预测

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
PubMed 文献 · Clin Infect Dis · 2020-01-01

本研究通过体外实验和生理药代动力学模型,比较氯喹与羟氯喹对SARS-CoV-2的抑制活性,并模拟羟氯喹在肺液中的浓度以探索最佳给药方案。结果显示羟氯喹体外抑制活性强于氯喹,模型预测负荷剂量400mg每日两次口服后维持200mg每日两次共4天可达有效浓度。

要点

  • 羟氯喹体外抑制SARS-CoV-2的EC50为0.72μM,强于氯喹的5.47μM。
  • PBPK模型预测羟氯喹口服负荷400mg bid后维持200mg bid共4天可达到有效肺浓度。
  • 该方案预测效力为氯喹磷酸盐500mg bid提前5天给药的3倍。

核心结论

  • 羟氯喹在体外抑制SARS-CoV-2的活性强于氯喹。

研究设计与样本

  • 体外实验使用SARS-CoV-2感染的Vero细胞测试氯喹和羟氯喹的药理活性。
  • 分别为两种药物建立生理药代动力学(PBPK)模型并整合体外数据。
  • 利用PBPK模型模拟5种给药方案下羟氯喹在肺液中的浓度。

主要发现

  • 羟氯喹的EC50为0.72 μM,氯喹的EC50为5.47 μM。
  • PBPK模型模拟显示,羟氯喹硫酸盐口服负荷剂量400 mg每日两次,随后维持剂量200 mg每日两次共4天,可达有效浓度。
  • 该方案预测效力为氯喹磷酸盐500 mg每日两次提前5天给药的3倍。

关键数值与推荐

  • 羟氯喹体外EC50 = 0.72 μM,氯喹体外EC50 = 5.47 μM。
  • 推荐方案:羟氯喹硫酸盐口服负荷400 mg每日两次,维持200 mg每日两次共4天。

临床怎么用

  • 基于体外和模型预测,羟氯喹可能用于SARS-CoV-2感染,但需临床验证。
  • 临床用药可参考负荷400 mg每日两次、维持200 mg每日两次共4天的方案。

局限性

  • 研究仅为体外实验和PBPK模型模拟,缺乏临床疗效和安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. PMID: 32150618. doi:10.1093/cid/ciaa237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。